

REMARKS

Claims 1-10 are pending in this application. Claims 4-5 and 8-9 are canceled. Claims 1, 2, 6, 7, and 10 are amended. Support for pyrimidine derivatives is found on page 8, line 17 of the specification. Claims 11-19 are added. Support for the active substances recited in claims 11-19 is found on pages 11 and 12 of the specification. No new matter is inserted into the application.

Entry of the above amendments is earnestly solicited. An early and favorable first action on the merits is earnestly solicited.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Kristi L. Rupert, Ph.D. (Reg. No. 45,702) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.


If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees

Application Number 10/084,095

required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Raymond C. Stewart, #21,066

KLR
RCS/KLR:gml
1060-0144P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s): Claim version with markings to show changes made

CLAIM VERSION WITH MARKINGS TO SHOW CHANGES MADE


In the claims:

Claims 4-5 and 8-9 are canceled.

Claims 11-19 are added.

The following claims are amended:

1. (Amended) A pharmaceutical composition having antitumor activity with reduced side effect(s) comprising an effective amount of a known active substance having antitumor effect selected from the group consisting of pyrimidine derivatives or, optionally [if desired and chemically possible], a pharmaceutically acceptable [suitable] acid addition salt [or a pharmaceutically suitable salt] thereof and an effective amount of a hydroximic acid derivative of the formula I



wherein

R¹ represents a hydrogen atom or a C₁₋₅ alkyl group,

R² stands for a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₈ cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or


R¹ and R² together with the nitrogen atom they are attached to form a 5 to 8 membered ring optionally containing one or more further nitrogen, oxygen or sulfur atom(s) and said ring can be condensed with another alicyclic or heterocyclic ring, preferably a benzene, naphthalene, quinoline, isoquinoline, pyridine or pyrazoline ring, furthermore optionally the nitrogen and/or sulfur heteroatom(s) are present in the form of an oxide or dioxide,

R³ means a hydrogen atom, a phenyl group, a naphthyl group or a pyridyl group wherein said groups can be substituted by one or more halo atom(s) or C₁₋₄ alkoxy group(s),

Y is a hydrogen atom, a hydroxy group, a C₁₋₂₄ alkoxy group optionally substituted by an amino group, a C₂₋₂₄ polyalkenyloxy group containing 1 to 6 double bond(s), a C₁₋₂₅ alkanoyl group, a C₃, alkenoyl group or a group of the formula R⁷-COO- wherein R⁷ represents a C₂₋₃₀ polyalkenyl group containing 1 to 6 double bond(s),

X stands for a halo atom, an amino group, a C₁₋₄ alkoxy group or X forms with B an oxygen atom, or

X and Y together with the carbon atom they are attached to and the -NR-O-CH₂- group being between said carbon atoms form a ring of the formula a




wherein

Z represents an oxygen atom or a nitrogen atom,

R stands for a hydrogen atom or

R forms with B a chemical bond,

A is a C₁₋₄ alkylene group or a chemical bond or a group of the formula b



wherein

R⁴ represents a hydrogen atom, a C₁₋₅ alkyl group, a C₃₋₈ cycloalkyl group or a phenyl group optionally substituted by a halo atom, a C₁₋₄ alkoxy group or a C₁₋₅ alkyl group,

R⁵ stands for a hydrogen atom, a C₁₋₄ alkyl group or a phenyl group,

m has a value of 0, 1 or 2,

n has a value of 0, 1 or 2,
or a pharmaceutically [physiologically] acceptable acid addition
salt thereof in admixture with one or more conventional carrier(s),
[with the proviso that the known active substance having antitumor
effect is other than cisplatin, carboplatin, paclitaxel, and
docetaxel, and]
wherein the antitumor activity is against tumors sensitive to the
combination.

2. (Amended) A pharmaceutical composition as claimed in
claim 1, comprising O-(3-piperidino-2-hydroxy-1-propyl)nicotinic
amidoxime or a pharmaceutically [physiologically] acceptable acid
addition salt thereof as the hydroximic acid derivative of the
formula I.

6. (Amended) A method for reducing the side effect(s) in a
patient requiring a treatment for a tumor comprising administering
an effective amount of a known active substance having antitumor
effect selected from the group consisting of pyrimidine derivatives
or, optionally, a pharmaceutically acceptable acid addition salt
thereof and an effective non-toxic amount of a hydroximic acid
derivative of the formula I, wherein R¹, R², R³, A, X, B, R and Y

are as defined in Claim 1, or a pharmaceutically [physiologically] acceptable acid addition salt thereof to the patient, [with the proviso that the known active substance having antitumor effect is other than cisplatin, carboplatin, paclitaxel, and docetaxel,] and wherein said tumor is sensitive to said active substance; and the administration of the hydroximic acid derivative or a pharmaceutically [physiologically] acceptable acid addition salt thereof reduces the side effects experienced by the patient requiring treatment for a tumor.

7. (Amended) A method as claimed in claim 6, wherein said active substance is [comprising administering] fluorouracil or a pharmaceutically acceptable salt thereof, and said hydroximic acid derivative is O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof [as the active substance having antitumor activity].

10. (Amended) A method as claimed in claim 6, wherein said hydroximic acid derivative is [comprising administering] O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically [physiologically] acceptable acid addition salt thereof [as the hydroximic acid derivative of the formula I].